Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker IPSC
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Roderick Wong | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | RTW Investments, LP | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Steven A. Cohen | 5.96M | 3.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 5.96M | 3.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Point72 Asset Management, L.P. | 5.96M | 3.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Steven A. Cohen | 5.96M | 6.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 5.96M | 6.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Point72 Asset Management, L.P. | 5.96M | 6.8% | SCHEDULE 13G/A ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Michael Kramarz | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Robert Egen Atkinson | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Commodore Capital Master LP | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Commodore Capital LP | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Bong Y. Koh | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Nimish Shah | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | VHCP Management EG, LLC | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | VHCP Management III, LLC | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | VHCP Co-Investment Holdings III, LLC | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 13.04M | 7.1% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 17.94M | 9.9% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Rajeev Shah | 17.94M | 9.9% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Peter Kolchinsky | 17.94M | 9.9% | SCHEDULE 13G ↗ |
| Jan 16, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | RA Capital Management, L.P. | 17.94M | 9.9% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Chen Yu | 17.75M | 9.9% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | TCG Crossover Fund III, L.P. | 8.88M | 4.9% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | TCG Crossover GP III, LLC | 8.88M | 4.9% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | TCG Crossover Fund II, L.P. | 8.88M | 4.9% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | TCG Crossover GP II, LLC | 8.88M | 4.9% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Deep Track Special Opportunities Fund, LP. | 2.88M | 1.6% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | David Kroin | 13.49M | 7.3% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 10.61M | 5.8% | SCHEDULE 13G ↗ |
| Jan 15, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Deep Track Capital, LP | 13.49M | 7.3% | SCHEDULE 13G ↗ |
| Jan 5, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Steven A. Cohen | 4.73M | 5.4% | SCHEDULE 13G ↗ |
| Jan 5, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 4.73M | 5.4% | SCHEDULE 13G ↗ |
| Jan 5, 2026 | SCHEDULE 13G | IPSC Century Therapeutics, Inc. | Point72 Asset Management, L.P. | 4.73M | 5.4% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Bain Capital Life Sciences Opportunities III, LP | 3.54M | 4.1% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Eli Casdin | 3.21M | 3.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Casdin Capital, LLC | 3.21M | 3.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Bong Y Koh | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Nimish Shah | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | VHCP Management EG, LLC | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | VHCP Management III, LLC | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | VHCP Co-Investment Holdings III, LLC | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | IPSC Century Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 3.96M | 4.7% | SCHEDULE 13G/A ↗ |
45 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances